The use of new drugs on elderly people - venturing on unknown territory;L'emploi d'un médicament nouveau chez les personnes âgées terra incognita

Gerontologie et Societe

Volumn 103, Issue 4, 2002, Pages 73-92

  Piette, Fraņois ^a   Quintrec, Jean Louis E ^b  

^a HÔPITAL CHARLES FOIX   (France)

^b Versailles Saint Quentin en Yvelines University   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 18244406855     PISSN: 01510193     EISSN: None     Source Type: Journal    
DOI: 10.3917/gs.103.0073     Document Type: Article

References (15)

1. BRITTON A, MCKEE M., BLACK N., MCPHERSON K., SANDERSON C, BAIN C. (April 1999). Threats to applicability of randomised trials : exclusions and selective participation. J. Health Sew. Res. Policy, volume 4, minier2 :112-121.
2. CAMERON H., MACPHEE GJA. (1995). Anticonvulsant therapy in the elderly - a need for placebo controlled trials. Epilepsy Res. ; 21 ; 149-57.
3. CHALMERS T.C (1990). Ethical implications of rejecting patients for clinical trials. Editorial---Journal of the American Medical Association ; 263:865.
4. FDA (Novembre 1989). Guideline for the study of drugs likely to he used in the elderly.
5. FOURRIER A., DEQUAE L., CHASLE- RIC A. et al (1993). Soclodermographle characteristics and polypharmacy*in elderly people: data from the PAQUID study. Post. Mark. Sum. ; 7:291-298.
6. GOUBIER-VIAL C, FERRY S. (1995). Analyse méthodologique des essais cliniques de phase IV entrepris à l'hôpital après ta lo i Huriet. Thérap le ; 50:151-162.
7. GURWITZ JH., COL NE, AVORN J. (1992). The exclusilon of the elderly and women from clinical trials In acute myocardial infarction. Journal of the American Association; 268:1417-1422.
8. CHYATT CH., KELLER JL., JAESCHKE R., ROSENBLOOM D., ADACHI JD., NEWHOUSE MT. (1990). The n-of-1 Randomized Controlled Trial: Clinical Usefulness. Annals of Internal Medicine; 112:293-299.
9. HORW1TZ RI., VISCOLI CM., CLEMENS JD , SADOCK RT. (1990). Developing improved observational methods for evaluating therapeutic effectiveness. American Journal of Medicine; 89 : 630-638.
10. HUTCH INS LE, UNGER MJ., CROX- LEY JJ. et al. (1999). Underrepresenta- tlon of patients 65 years of ag or older In cancer treatment trials. B.MJ. ; 341:2061- 2067.
11. ICH (1994). Note for guidance on studies in support of special populations. Geriatrics.
12. LASSALE C, PIETTE E, JOLLIET P. (2001 ). Les effets des médicaments chez les sujets âgés : de la cible pharmacolo- gtque au bénéfice/risque. Thérapie; 56: '363-367.
13. PIETTE F., HAMON-VILCOT ES. (1996). Le vieillard et les médicaments. In : Traité de Médecine 3e édition, Médecine- Sciences Flammarion, 1996; chapitre 70: 316-322.
14. ROCHON PA., ANDERSON CM., TU JV., GURWITZ )H., CLARK JP, SHEAR NH., LAU P. (1999). Age - and Gender - Related Use of Low-Dose Drug Therapy : The Need to Manufacture Low-Dose Therapy and Evaluate the Minimum Effective Dose. JAGS, 47, n" 8:954-959. TEMPLE R. (1987). The clinical investigation of drugs for use by the elderly ; food and drug guidelines. Clin. Pharmacol. Ther.; 42:681-685.
15. YUSUF S., HELD P., TEO KK. (1990). Selection of patients for randomized controlled trials: Implications of wide or narrow eligibility criteria. Statistics in Medicine; 9 ;73-86.